Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Michael Jackson
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Living Beings
Chemicals & Drugs
Disorders
Activities & Behaviors
Anatomy
Concepts & Ideas
Physiology
Sign-in to see full Profile
Network (preview)
27
Jenner, Peter
17
Smith, Lance
9
Rose, Sarah
9
iravani, mahmoud
7
Pearce, R K B
6
Al-Barghouthy, Ghassan
4
Kuoppamäki, Mikko
3
Kuwana, Yoshihisa
3
Kanda, T
3
Kase, Hiroshi
3
Cheetham, Sharon
3
Hansard, Matthew
2
Costa, Sergio
2
Cannizzaro, Carla
2
Maratos, Eleni
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Michael Jackson (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Stockwell K A; Scheller D; Rose S; Jackson M J; Tayarani-Binazir K; Iravani M M; Smith L A; Olanow C W; Jenner P
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Experimental neurology 2009;219(2):533-42.
-
2008: Stockwell K A; Virley D J; Perren M; Iravani M M; Jackson M J; Rose S; Jenner P
Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
Experimental neurology 2008;211(1):172-9.
-
2007: Zubair Mohammed; Jackson Michael J; Tayarani-Binazir Kayhan; Stockwell Kim A; Smith Lance A; Rose Sarah; Olanow Warren; Jenner Peter
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Experimental neurology 2007;208(2):177-84.
-
2007: Kuoppamäki M; Al-Barghouthy G; Jackson M J; Smith L A; Quinn N; Jenner P
L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates.
Journal of neural transmission (Vienna, Austria : 1996) 2007;114(9):1147-53.
-
2007: Jackson Michael J; Smith Lance A; Al-Barghouthy Ghassan; Rose Sarah; Jenner Peter
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
Experimental neurology 2007;204(1):162-70.
-
2006: Iravani Mahmoud M; Tayarani-Binazir Kayhan; Chu Wing B; Jackson Michael J; Jenner Peter
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
The Journal of pharmacology and experimental therapeutics 2006;319(3):1225-34.
-
2006: Iczkiewicz Joanna; Jackson Michael J; Smith Lance A; Rose Sarah; Jenner Peter
Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease.
Brain research 2006;1118(1):239-50.
-
2006: Smith Lance A; Jackson Michael J; Johnston Louisa; Kuoppamaki Mikko; Rose Sarah; Al-Barghouthy Ghassan; Del Signore Susanna; Jenner Peter
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
Clinical neuropharmacology 2006;29(3):112-25.
-
2006: Zeng B-Y; Iravani M M; Lin S-T; Irifune M; Kuoppamäki M; Al-Barghouthy G; Smith L; Jackson M J; Rose S; Medhurst A D; Jenner P
MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome.
The European journal of neuroscience 2006;23(7):1766-74.
-
2005: Iravani Mahmoud M; Costa Sergio; Al-Bargouthy Ghassan; Jackson Michael J; Zeng Bai-Yun; Kuoppamäki Mikko; Obeso Jose A; Jenner Peter
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
The European journal of neuroscience 2005;22(6):1305-18.
-
2005: Smith Lance A; Jackson Michael J; Al-Barghouthy Ghassan; Rose Sarah; Kuoppamaki Mikko; Olanow Warren; Jenner Peter
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Movement disorders : official journal of the Movement Disorder Society 2005;20(3):306-14.
-
2005: Iravani Mahmoud M; Syed Emilie; Jackson Michael J; Johnston Louisa C; Smith Lance A; Jenner Peter
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
The European journal of neuroscience 2005;21(4):841-54.
-
2004: Jackson Michael J; Al-Barghouthy Ghassan; Pearce Ronald K B; Smith Lance; Hagan James J; Jenner Peter
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
Pharmacology, biochemistry, and behavior 2004;79(3):391-400.
-
2004: Hansard Matthew J; Smith Lance A; Jackson Michael J; Cheetham Sharon C; Jenner Peter
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Movement disorders : official journal of the Movement Disorder Society 2004;19(1):15-21.
-
2003: Iravani Mahmoud M; Jackson Michael J; Kuoppamäki Mikko; Smith Lance A; Jenner Peter
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2003;23(27):9107-15.
-
2003: Maratos Eleni C; Jackson Michael J; Pearce Ronald K B; Cannizzaro Carla; Jenner Peter
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Experimental neurology 2003;179(1):90-102.
-
2002: Hansard Matthew J; Smith Lance A; Jackson Michael J; Cheetham Sharon C; Jenner Peter
Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
The Journal of pharmacology and experimental therapeutics 2002;303(3):952-8.
-
2002: Smith Lance A; Tel Banu C; Jackson Michael J; Hansard Matthew J; Braceras Rogelio; Bonhomme Céline; Chezaubernard Claire; Del Signore Susanna; Rose Sarah; Jenner Peter
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
Movement disorders : official journal of the Movement Disorder Society 2002;17(5):887-901.
-
2002: Hansard Matthew J; Smith Lance A; Jackson Michael J; Cheetham Sharon C; Jenner Peter
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.
European journal of pharmacology 2002;451(2):157-60.
-
2002: Smith L A; Jackson M J; Al-Barghouthy G; Jenner P
The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration.
Journal of neural transmission (Vienna, Austria : 1996) 2002;109(2):123-40.
-
2002: Dass B; Iravani M M; Jackson M J; Engber T M; Galdes A; Jenner P
Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Neuroscience 2002;114(1):99-109.
-
2001: Maratos E C; Jackson M J; Pearce R K; Jenner P
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
Movement disorders : official journal of the Movement Disorder Society 2001;16(4):631-41.
-
2001: Iravani M M; Costa S; Jackson M J; Tel B C; Cannizzaro C; Pearce R K; Jenner P
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
The European journal of neuroscience 2001;13(3):597-608.
-
2000: Kanda T; Jackson M J; Smith L A; Pearce R K; Nakamura J; Kase H; Kuwana Y; Jenner P
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Experimental neurology 2000;162(2):321-7.
-
1999: Kuwana Y; Shiozaki S; Kanda T; Kurokawa M; Koga K; Ochi M; Ikeda K; Kase H; Jackson M J; Smith L A; Pearce R K; Jenner P G
Antiparkinsonian activity of adenosine A2A antagonists in experimental models.
Advances in neurology 1999;80():121-3.
-
1998: Kanda T; Jackson M J; Smith L A; Pearce R K; Nakamura J; Kase H; Kuwana Y; Jenner P
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
Annals of neurology 1998;43(4):507-13.
-
1997: Mackenzie G M; Jackson M J; Jenner P; Marsden C D
Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
Synapse (New York, N.Y.) 1997;26(3):301-16.
Sign-in to see more
